Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totalling 1,830,000 shares, an increase of 39.7% from the March 31st total of 1,310,000 shares. Based on an average daily volume of 121,900 shares, the days-to-cover ratio is currently 15.0 days. Approximately 23.1% of the company’s stock are sold short.

Analyst Ratings Changes

KPTI has been the subject of a number of analyst reports. Robert W. Baird decreased their target price on shares of Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating for the company in a research report on Monday, March 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 target price on shares of Karyopharm Therapeutics in a research report on Thursday, February 20th. Finally, HC Wainwright increased their price target on Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $57.50.

Karyopharm Therapeutics Price Performance

Shares of KPTI opened at $7.36 on Friday. The company has a market cap of $63.08 million, a PE ratio of -7.22 and a beta of 0.32. The firm has a 50-day moving average of $5.69 and a 200-day moving average of $9.22. Karyopharm Therapeutics has a one year low of $3.51 and a one year high of $18.00.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Wednesday, February 19th. The company reported ($3.60) EPS for the quarter, topping analysts’ consensus estimates of ($3.90) by $0.30. The business had revenue of $30.54 million for the quarter, compared to the consensus estimate of $30.29 million. Analysts expect that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several hedge funds have recently added to or reduced their stakes in KPTI. Geode Capital Management LLC raised its position in shares of Karyopharm Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock valued at $1,125,000 after purchasing an additional 43,856 shares during the period. Two Sigma Advisers LP grew its stake in Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after buying an additional 45,400 shares during the last quarter. Northern Trust Corp raised its holdings in Karyopharm Therapeutics by 23.5% in the 4th quarter. Northern Trust Corp now owns 283,729 shares of the company’s stock valued at $192,000 after acquiring an additional 54,061 shares during the period. Jane Street Group LLC lifted its position in Karyopharm Therapeutics by 265.5% during the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock worth $506,000 after acquiring an additional 543,556 shares during the last quarter. Finally, Focus Partners Wealth bought a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth approximately $31,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).